




NaDeNo

NANOSCIENCE AS



A 2022 SINTEF spin-off

UNLEASHING THE POTENTIAL OF HARD TO DELIVER DRUGS

Non-confidential July 2023



NaDeNo based on decades of research




NaDeNo's proprietary nanoparticle platform

The concept

Hydrophobic drugs **encapsulated** in polymeric nanoparticles, injected into the body by various administration routes.


No chemical modification of drug.

Nanoparticles **degrade** in the body □ drug is **released** over time.




The impact

- ✓ Protection of drug and patient
- ✓ Increased efficacy
- ✓ Novel delivery opportunities for new and existing hard-to-deliver drugs
- ✓ Possibilities for prolonged drug patent protection




PACAB-002 for treatment of cancer with high unmet need


- Encapsulated anti-cancer **cabazitaxel** for **local delivery**
- **Proven**
 - ✓ Long drug retention time
 - ✓ Tumor-specific drug accumulation
 - ✓ Reduced side effects
 - ✓ Even intraperitoneal distribution
 - ✓ Significant effect in mouse models



1 hr after injection of fluorescently-labelled nanoparticles




Peritoneal metastasis originating from ovarian cancer. Tumor weight at study end (day 38), N=6 mice in each group * $P < .001$




Our nanotechnology can make a difference


‘The majority of these patients will die of their disease’ KOL –US



Lead candidate for peritoneal metastasis 600 mUSD



5% licensing fee is substantial even at small penetration rates



NaDeNo has several programs in motion


RoA	API	Indication	Discovery	Proof of concept	Preclinical	Clinical Phase I/II
<u>Proprietary therapeutic programs - oncology</u>						
Local (i.p)	Cabazitaxel	Peritoneal metastasis	<div>PACAB-002</div>			Target 2025
Undisclosed	Undisclosed	Undisclosed	<div><div></div><div>Nondilutive funding</div></div>			Target 2025
<u>Proprietary drug delivery platform – new proprietary combinations - available for licensing</u>						
Based on POC		<div></div>				

The blue arrows indicate today's status

Together we can do more!



**Partners
for pipeline and
platform
development**




**Seed II
Q4 2023
5 m USD**

Technology for hard to deliver drugs

Contact:

CEO: annbjorg.falck@nadenno.com

Scientific Advisor: ruth.b.schmid@sintef.no



NaDeNo